Histogen Stock In The News
| HSTO Stock | USD 0.02 0.01 25.65% |
Our overall analysis of Histogen's news coverage and content from conventional and social sources shows investors' bearish mood towards Histogen. The specific impact of Histogen news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Histogen's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Histogen headlines in addition to utilizing other, more conventional financial analysis modules. Check out Histogen Backtesting and Histogen Hype Analysis. To learn how to invest in Histogen Stock, please use our How to Invest in Histogen guide.
Histogen |
Histogen Today Top News and Investor Outlook
Histogen Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Histogen and other traded companies coverage with news coverage. We help investors stay connected with Histogen headlines for the 23rd of November to make an informed investment decision based on correlating the impacts of news items on Histogen Stock performance. Please note that trading solely based on the Histogen hype is not for everyone as timely availability and quick action are needed to avoid losses.
Histogen stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Histogen earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Histogen that are available to investors today. That information is available publicly through Histogen media outlets and privately through word of mouth or via Histogen internal channels. However, regardless of the origin, that massive amount of Histogen data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Histogen news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Histogen relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Histogen's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Histogen alpha.
Histogen Largest EPS Surprises
Earnings surprises can significantly impact Histogen's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-03-09 | 2022-12-31 | -0.79 | -0.61 | 0.18 | 22 | ||
2022-11-10 | 2022-09-30 | -1.26 | -1.01 | 0.25 | 19 | ||
2023-11-09 | 2023-09-30 | -0.54 | -0.9 | -0.36 | 66 | ||
2023-08-10 | 2023-06-30 | -0.9 | -0.49 | 0.41 | 45 | ||
2021-11-10 | 2021-09-30 | -2.3 | -1.8 | 0.5 | 21 | ||
2022-03-10 | 2021-12-31 | -2.1 | -1.4 | 0.7 | 33 |
Histogen Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Histogen Stock. Current markets are strongly bullish. About 89% of major world exchanges and indexes are currently up. See today's market update for more information.
21st of November 2024
Cingulate Raised to Buy at Maxim Group at thelincolnianonline.com
20th of November 2024
Virax Biolabs Sees Asset Growth Amid Financial Loss - TipRanks at news.google.com
20th of November 2024
Aileron Therapeutics Reports Q3 2024 Financial Results - MSN at news.google.com
20th of November 2024
Artelo Biosciences Stock Surges Amid Strong Buy Ratings - GuruFocus.com at news.google.com
20th of November 2024
Senti Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months End... at news.google.com
18th of November 2024
Disposition of 4558 shares by Jones Mitchell Lawrence of Palisade Bio subject to Rule 16b-... at MacroaxisInsider
18th of November 2024
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on ... at gurufocus.com
15th of November 2024
Curis, Inc. Q3 2024 Earnings Call Transcript at insidermonkey.com
15th of November 2024
Tempest Therapeutics, Inc. Short Interest Update at thelincolnianonline.com
14th of November 2024
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlight... at globenewswire.com
13th of November 2024
Student arrested for trying to sneak meth-soaked T-shirts through LAX in hidden compartmen... at nypost.com
11th of November 2024
Aileron Therapeutics Stock Declines Amidst Mixed Sector Performance at gurufocus.com
8th of November 2024
Earnings call Rigel Pharmaceuticals reports strong Q3 growth, plans expansion at investing.com
7th of November 2024
Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the ... at finance.yahoo.com
6th of November 2024
Sonnet BioTherapeutics Announces Pricing of 5.0 Million Underwritten Public Offering Price... at finance.yahoo.com
4th of November 2024
Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute t... at finance.yahoo.com
29th of October 2024
Curis looks to raise 12.1M in private placement at seekingalpha.com
24th of October 2024
Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular T... at finance.yahoo.com
21st of October 2024
CYTO stock plunges to 52-week low, hitting 0.57 amid market challenges - Investing.com at news.google.com
18th of October 2024
Whats Going On With Bright Minds Biosciences Stock Friday at benzinga.com
17th of October 2024
Tonix stock climbs 6 percent on first payment under 34M DOD contract at seekingalpha.com
16th of October 2024
Artelo Biosciences Stock Surges Amid Bullish Analyst Ratings at gurufocus.com
16th of October 2024
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C2A mixed agonist, demonstrat... at globenewswire.com
11th of October 2024
Entera Bio Earns Buy Rating from HC Wainwright at thelincolnianonline.com
10th of October 2024
Discretionary transaction by Ellias Helen K. of 2857142 shares of SAB Biotherapeutics at 0... at MacroaxisInsider
10th of October 2024
Tempest stock gains on Roche collaboration at seekingalpha.com
10th of October 2024
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program,... at globenewswire.com
8th of October 2024
Cingulates Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show at globenewswire.com
30th of September 2024
Acquisition by Brams Matthew of 1000 shares of Cingulate at 5.04 subject to Rule 16b-3 at MacroaxisInsider
27th of September 2024
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification... at finance.yahoo.com
27th of September 2024
Palisade Bio inks new deal with CEO Finley terms disclosed - Investing.com India at news.google.com
26th of September 2024
ENTX OPK Stock May Gain Following Positive PKPD Research Data at finance.yahoo.com
25th of September 2024
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split at globenewswire.com
23rd of September 2024
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altam... at kalkinemedia.com
20th of September 2024
Is Entera Bio Stock Outpacing Its Medical Peers This Year - MSN at news.google.com
20th of September 2024
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635 at globenewswire.com
17th of September 2024
Altamira Therapeutics Announces Pricing of up to 12.0 Million Public Offering at globenewswire.com
16th of September 2024
Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market M... at finance.yahoo.com
13th of September 2024
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference - ... at news.google.com
30th of August 2024
Sonnet BioTherapeutics gets extension to meet Nasdaq rule - Investing.com at news.google.com
24th of May 2024
YS Biopharma to change legal name to LakeShore Biopharma at seekingalpha.com
15th of May 2024
TRACON Pharmaceuticals Inc Q1 2024 Earnings Call Transcript Highlights Strategic ... at gurufocus.com
7th of May 2024
Insider Trading at benzinga.com
10th of April 2024
UPDATE 1-US airlines seek FAA extension of New York minimum flight requirements cuts -lett... at finance.yahoo.com
10th of July 2023
Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2HER... at news.google.com
3rd of July 2023
Timber Pharmaceuticals Discloses Communication From NYSE American at globenewswire.com
30th of June 2023
Baudax Bio Acquires TeraImmune, Inc. at globenewswire.com
1st of May 2023
Baudax Bio Announces Closing of 4 Million Public Offering at finance.yahoo.com
27th of April 2023
Hillstream BioPharma, Inc. Short Interest Update at thelincolnianonline.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Histogen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Histogen's short interest history, or implied volatility extrapolated from Histogen options trading.
Check out Histogen Backtesting and Histogen Hype Analysis. To learn how to invest in Histogen Stock, please use our How to Invest in Histogen guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Histogen. If investors know Histogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Histogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.81) | Revenue Per Share 0.004 | Return On Assets (0.54) | Return On Equity (1.20) |
The market value of Histogen is measured differently than its book value, which is the value of Histogen that is recorded on the company's balance sheet. Investors also form their own opinion of Histogen's value that differs from its market value or its book value, called intrinsic value, which is Histogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Histogen's market value can be influenced by many factors that don't directly affect Histogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Histogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Histogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Histogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.